Fig. 3
Protein quantification and stability in upper respiratory tract samples for both studies (FVL and LSPDV). (A) Determination of proteins by the Bradford method at day one, in 23 healthy participants. OS: oropharyngeal swab (n = 23), NA: nasopharyngeal aspirate (n = 21), SA: Saliva (n = 7). Data are represented as the mean ± SEM and statistical significance was estimated by Kruskal–Wallis test. *: p < 0.05, ***: p < 0.001. Determination of protein concentration by the Bradford assay. (B) Quantification of proteins in nasopharyngeal aspirates samples from four healthy donors (HD) in FVL study. (C) Quantification of proteins in oropharyngeal swab samples from two healthy donors in FVL study. Statistical significance was estimated by Kruskal–Wallis test. *: p < 0.05. Determination of protein integrity by electrophoresis. (D) Polyacrylamide gel electrophoresis on a 12% SDS denaturing gel with silver staining from two healthy donors in FVL study at 1 (fresh), 7 and 15 days. M: marker, NA: nasopharyngeal aspirate, OS: oropharyngeal swab. (E) Determination of proteins by the Bradford method from Nasopharyngeal swabs (NS) from 7 SARS-CoV-2 positive participants and 1 healthy participant in LSPDV study, received July 25 of 2022. F Polyacrylamide gel electrophoresis on a 12% SDS denaturing gel with silver staining from samples 7 and 8 in LSPDV study. M: marker, NA: nasopharyngeal swab.
